Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1016764614 | 10167646 | 14 | F | 2013 | 20160817 | 20140512 | 20160822 | EXP | PHHY2012CA078099 | NOVARTIS | 0.00 | M | Y | 0.00000 | 20160822 | CN | COUNTRY NOT SPECIFIED | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1016764614 | 10167646 | 1 | PS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG, QD | 21588 | 400 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 2 | SS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG, QD | 21588 | 400 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 3 | SS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG, QD | 21588 | 400 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 4 | SS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG, QD | 21588 | 400 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 5 | SS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG, QD | 21588 | 400 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 6 | SS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 200 MG, QD | 21588 | 200 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 7 | SS | GLEEVEC | IMATINIB MESYLATE | 1 | Unknown | 300 MG, QD | 21588 | 300 | MG | TABLET | QD | ||||||
| 1016764614 | 10167646 | 8 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1016764614 | 10167646 | 1 | Gastrointestinal stromal tumour |
| 1016764614 | 10167646 | 8 | Gastric pH decreased |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1016764614 | 10167646 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1016764614 | 10167646 | Abdominal pain | |
| 1016764614 | 10167646 | Bladder disorder | |
| 1016764614 | 10167646 | Feeling abnormal | |
| 1016764614 | 10167646 | Fistula | |
| 1016764614 | 10167646 | Gastrointestinal stromal tumour | |
| 1016764614 | 10167646 | Inflammation | |
| 1016764614 | 10167646 | Intestinal perforation | |
| 1016764614 | 10167646 | Malignant neoplasm progression | |
| 1016764614 | 10167646 | Metastases to liver | |
| 1016764614 | 10167646 | Metastasis | |
| 1016764614 | 10167646 | Muscle spasms | |
| 1016764614 | 10167646 | Recurrent cancer | |
| 1016764614 | 10167646 | Renal disorder | |
| 1016764614 | 10167646 | Skin burning sensation | |
| 1016764614 | 10167646 | Sunburn |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1016764614 | 10167646 | 1 | 200804 | 2010 | 0 | |
| 1016764614 | 10167646 | 2 | 201209 | 20140404 | 0 | |
| 1016764614 | 10167646 | 3 | 201407 | 0 | ||
| 1016764614 | 10167646 | 4 | 20141202 | 0 | ||
| 1016764614 | 10167646 | 5 | 20151221 | 201602 | 0 | |
| 1016764614 | 10167646 | 6 | 20160401 | 0 |